Back to all papers

Cardiac imaging biomarkers of heart failure in diabetes for phenotyping, risk stratification, and evaluating therapeutic response.

August 24, 2026pubmed logopapers

Authors

Glidden MD,Connelly KA,Sengupta P,Hoori A,Wilson D,Rashid I,Rajagopalan S

Affiliations (6)

  • University Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Keenan Research Centre and Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Division of Cardiology, Rutgers Robert Wood Johnson Medical School and University Hospital, New Brunswick, NJ, USA.
  • Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
  • University Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, OH, USA. [email protected].
  • Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. [email protected].

Abstract

Type 2 diabetes mellitus (T2DM) is a well-established risk factor for the development of heart failure (HF), yet HF risk within this population is highly heterogeneous. Appropriate biomarker selection and a limited mechanistic understanding of the phenotypic subtypes of HF in T2DM remain barriers to both risk stratification and therapeutic development. Cardiac imaging-based biomarkers are emerging as versatile tools for assessing myocardial dysfunction in T2DM and may enable a shift toward non-invasive, comprehensive, and precise disease assessment. Advances in cardiac MRI, echocardiography, CT, PET, and metabolic imaging have enhanced detection of myocardial fibrosis, diastolic dysfunction, and early functional impairment, as well as assessment of response to contemporary metabolic therapies. This review synthesizes recent imaging evidence to deepen our understanding of HF mechanisms in T2DM and to improve early risk stratification and surveillance strategies. Artificial intelligence-based imaging applications in T2DM with HF and other cardiomyopathies, including radiomics analyses and prediction tasks, will also be discussed with respect to their potential to further refine HF phenotyping and risk assessment.

Topics

Heart FailureDiabetes Mellitus, Type 2Cardiac Imaging TechniquesDiabetic CardiomyopathiesJournal ArticleReview

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.